New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

CRISPR Therapeutics AG

Contributing Author

Recent Articles by CRISPR Therapeutics AG

Mar-11	CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering CRSP -5.44% GlobeNewswire
Mar-10	CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering CRSP -10.17% GlobeNewswire
Feb-12	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results CRSP +8.46% CRSP GlobeNewswire
Jan-12	CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones CRSP GlobeNewswire
Jan-05	CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference CRSP GlobeNewswire
Dec-22	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies CRSP GlobeNewswire
Nov-10	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results CRSP GlobeNewswire
Nov-08	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering CRSP GlobeNewswire
Oct-10	CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform CRSP GlobeNewswire
Oct-01	CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress CRSP GlobeNewswire
Sep-22	CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe CRSP GlobeNewswire
Sep-09	CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 CRSP GlobeNewswire
Sep-02	CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
Aug-04	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results CRSP -6.71% CRSP +6.24% GlobeNewswire
Jun-30	CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025 CRSP GlobeNewswire
Jun-26	CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline CRSP GlobeNewswire
May-29	CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
May-19	CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRSP GlobeNewswire
May-06	CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3 CRSP -11.86% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)